Pharmacologic therapeutics for cardiac reperfusion injury (Q36944008)

17 August 2017

1 reference

title

Pharmacologic therapeutics for cardiac reperfusion injury (English)

1 reference

17 August 2017

Eric R Gross

1

1 reference

17 August 2017

Garrett J Gross

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Emerging Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

12

1 reference

17 August 2017

issue

3

1 reference

17 August 2017

page(s)

367-388

1 reference

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Does reperfusion injury exist in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Reperfusion injury: does it exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Amp 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Coronary artery disease and opioid use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Tissue distribution of opioid receptor gene expression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Ligand triggers of classical preconditioning and postconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning--a brief review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Role of bradykinin in preconditioning and protection of the ischaemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Upregulation of bradykinin B1-receptor expression after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Protective effects of erythropoietin in cardiac ischemia: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Glucose-insulin-potassium reduces infarct size when administered during reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Cardioprotection by glucose-insulin-potassium: dependence on KATP channel opening and blood glucose concentration before ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Effect of halothane on myocardial reoxygenation injury in the isolated rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Anesthetic myocardial protection with sevoflurane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Cardioprotection by volatile anesthetics: new applications for old drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Statin mediated protection of the ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

KATP channels and myocardial preconditioning: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase--dependent pathway is cardioprotective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Acute PKCdelta inhibition limits ischaemia-reperfusion injury in the aged rat heart: role of GSK-3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

The influence of B-cell lymphoma 2 protein, an antiapoptotic regulator of mitochondrial permeability transition, on isoflurane-induced and ischemic postconditioning in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

The PI3K-PDK1 connection: more than just a road to PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

GSK3 takes centre stage more than 20 years after its discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Mitochondrial permeability transition pore and postconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Role of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.367

10.1517/14728214.12.3.367

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference